,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABLIM2,KIAA1808,ENSG00000163995,Actin binding LIM protein family member 2,4,7965310-8158832,Predicted intracellular proteins,Evidence at protein level,HPA035808,Uncertain,,Approved,Nucleoplasm<br>Mitochondria,,Mixed,Tissue enhanced,,skeletal muscle: 37.5;spleen: 28.4,cerebral cortex: 22.1,Group enriched,6.0,SCLC-21H: 16.3;SiHa: 6.6;U-2197: 19.7
1,AC007325.4,,ENSG00000278817,,Unmapped,131494-137392,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,cerebral cortex: 27.4;heart muscle: 34.4;skeletal muscle: 40.5,thyroid gland: 14.9,Cell line enhanced,,A549: 14.5;T-47d: 10.8
2,ACHE,YT,ENSG00000087085,Acetylcholinesterase (Cartwright blood group),7,100889994-100896974,"Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA019704, HPA027098",,,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)",Mixed,Tissue enhanced,,skeletal muscle: 58.5,cerebral cortex: 14.1,Cell line enhanced,,BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
3,ADCY2,"AC2, HBAC2, KIAA1060",ENSG00000078295,Adenylate cyclase 2,5,7396208-7830081,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB031482, HPA038015, HPA038483",Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 57.2;skeletal muscle: 23.6,prostate: 8.4,Group enriched,7.0,AF22: 5.6;NTERA-2: 4.3;SK-MEL-30: 3.8
4,AGBL1,"CCP4, FLJ32310",ENSG00000273540,ATP/GTP binding protein like 1,15,86079973-87029052,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,lung: 1.3;skeletal muscle: 4.4,esophagus: 1.0,Not detected,,
5,AGL,,ENSG00000162688,"Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase",1,99850084-99924023,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA028498, HPA054340",Approved,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:1.73e-10 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 90.3,parathyroid gland: 35.1,Mixed,,
6,ALPK2,HAK,ENSG00000198796,Alpha kinase 2,18,58481247-58628957,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027377, HPA027976, HPA028084, HPA029801",Uncertain,,Approved,Cytosol,Renal cancer:8.20e-5 (unfavourable),Tissue enriched,Tissue enhanced,,heart muscle: 28.6;skeletal muscle: 14.1,lymph node: 6.9,Cell line enhanced,,BJ: 44.5;BJ hTERT+: 25.8;fHDF/TERT166: 37.1;U-138 MG: 25.6
7,ALPK3,"KIAA1330, MAK, Midori",ENSG00000136383,Alpha kinase 3,15,84816680-84873482,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026558,Uncertain,,Approved,Nucleus,Renal cancer:3.95e-7 (favourable),Mixed,Tissue enhanced,,heart muscle: 32.8;parathyroid gland: 36.2;skeletal muscle: 47.6,adipose tissue: 12.3,Cell line enhanced,,BEWO: 12.8;HUVEC TERT2: 12.1;LHCN-M2: 16.5;NTERA-2: 12.1;RH-30: 34.1
8,ART3,,ENSG00000156219,ADP-ribosyltransferase 3,4,76011184-76112802,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA011268,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 77.0;testis: 174.4,heart muscle: 29.1,Group enriched,7.0,NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9
9,ASB14,DKFZp313L0121,ENSG00000239388,Ankyrin repeat and SOCS box containing 14,3,57268347-57292682,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,skeletal muscle: 9.9,heart muscle: 2.4,Not detected,,
10,ASB15,FLJ43370,ENSG00000146809,Ankyrin repeat and SOCS box containing 15,7,123567010-123639481,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,heart muscle: 19.2;skeletal muscle: 43.9,kidney: 7.5,Not detected,,
11,ASB2,ASB-2,ENSG00000100628,Ankyrin repeat and SOCS box containing 2,14,93934153-93976791,Predicted intracellular proteins,Evidence at protein level,,,,,,Endometrial cancer:3.62e-6 (favourable),Mixed,Tissue enhanced,,skeletal muscle: 85.8,smooth muscle: 25.6,Cell line enhanced,,Karpas-707: 7.3;RPMI-8226: 6.6;U-266/70: 21.0;U-266/84: 4.6
12,ASB5,,ENSG00000164122,Ankyrin repeat and SOCS box containing 5,4,176213673-176277571,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA028870,,,Approved,Plasma membrane,Head and neck cancer:5.67e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,skeletal muscle: 75.7,prostate: 20.8,Cell line enriched,14.0,LHCN-M2: 986.5
13,BEST3,"MGC13168, MGC40411, VMD2L3",ENSG00000127325,Bestrophin 3,12,69643360-69699476,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA054582,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 16.3;skeletal muscle: 12.2,testis: 5.6,Group enriched,13.0,REH: 32.4;RPMI-8226: 26.4;U-698: 43.2
14,C1orf127,FLJ37118,ENSG00000175262,Chromosome 1 open reading frame 127,1,10946471-10982037,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA027654,Uncertain,,,,,Tissue enriched,Tissue enhanced,,skeletal muscle: 5.7,stomach: 2.1,Cell line enhanced,,THP-1: 1.7
15,C1QTNF9,"AQL1, C1QTNF9A, CTRP9, MGC48915",ENSG00000240654,C1q and tumor necrosis factor related protein 9,13,24307166-24322535,Predicted secreted proteins,Evidence at protein level,HPA056632,Uncertain,,,,,Not detected,Tissue enhanced,,skeletal muscle: 2.9,adipose tissue: 2.1,Not detected,,
16,CAND2,"KIAA0667, TIP120B, Tp120b",ENSG00000144712,Cullin associated and neddylation dissociated 2 (putative),3,12796472-12871916,Predicted intracellular proteins,Evidence at protein level,HPA005777,Approved,,Approved,Nuclear bodies<br>Cytosol,,Mixed,Tissue enhanced,,skeletal muscle: 42.3;testis: 29.3,heart muscle: 16.3,Cell line enhanced,,HEK93: 18.6;REH: 11.8
17,CAP2,,ENSG00000112186,"CAP, adenylate cyclase-associated protein, 2 (yeast)",6,17393216-17557792,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA050530, HPA054147",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 125.1;skeletal muscle: 220.8,heart muscle: 70.1,Mixed,,
18,CAPN3,"CANP3, LGMD2, LGMD2A, nCL-1, p94",ENSG00000092529,Calpain 3,15,42359500-42412318,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA040052,Enhanced,,,,,Tissue enriched,Tissue enhanced,,epididymis: 217.3;skeletal muscle: 336.8,skin: 92.9,Cell line enriched,27.0,SK-MEL-30: 202.7
19,CCDC28B,"MGC1203, RP4-622L5.5",ENSG00000160050,Coiled-coil domain containing 28B,1,32200386-32205387,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA028589,Uncertain,,,,"Pancreatic cancer:1.10e-5 (favourable), Breast cancer:2.92e-4 (favourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 40.8,testis: 22.7,Mixed,,
20,CEP85,"CCDC21, DKFZP434L0117",ENSG00000130695,Centrosomal protein 85,1,26234153-26279038,Predicted intracellular proteins,Evidence at protein level,HPA028252,Approved,,Supported,Nucleoli<br>Golgi apparatus<br>Microtubule organizing center<br>Cytosol,Liver cancer:4.39e-6 (unfavourable),Expressed in all,Tissue enhanced,,skeletal muscle: 48.1;testis: 52.4,heart muscle: 17.5,Expressed in all,,
21,CFAP46,"bA288G11.4, bA288G11.5, bB137A17.2, bB137A17.3, C10orf123, C10orf124, C10orf92, C10orf93, DKFZp434A1721, FLJ25954, TTC40",ENSG00000171811,Cilia and flagella associated protein 46,10,132808392-132942823,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA037786, HPA038034, HPA038867, HPA038868",Uncertain,,,,,Mixed,Tissue enhanced,,fallopian tube: 11.7;skeletal muscle: 11.4;testis: 23.8,thyroid gland: 4.5,Cell line enhanced,,HAP1: 1.0;SH-SY5Y: 1.0
22,CHRNA1,CHRNA,ENSG00000138435,Cholinergic receptor nicotinic alpha 1 subunit,2,174747592-174787935,"Disease related genes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071554,Enhanced,,Supported,Plasma membrane,,Tissue enhanced,Tissue enhanced,,prostate: 3.2;skeletal muscle: 7.2,colon: 1.5,Group enriched,23.0,LHCN-M2: 370.9;RH-30: 348.5
23,CLIC5,DFNB102,ENSG00000112782,Chloride intracellular channel 5,6,45898451-46080395,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA074371,,,Supported,Nuclear speckles<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,lung: 116.1;skeletal muscle: 119.2,heart muscle: 76.0,Group enriched,7.0,CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5
24,CLTCL1,"CHC22, CLH22, CLTCL, CLTD",ENSG00000070371,Clathrin heavy chain like 1,22,19179473-19291716,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA075795,,,Approved,Vesicles,,Mixed,Tissue enhanced,,skeletal muscle: 24.1;testis: 49.4,bone marrow: 10.4,Cell line enhanced,,HMC-1: 56.9
25,CORO6,FLJ14871,ENSG00000167549,Coronin 6,17,29614756-29622907,Predicted intracellular proteins,Evidence at protein level,HPA021556,,,Supported,Golgi apparatus,Renal cancer:9.61e-7 (unfavourable),Tissue enhanced,Tissue enhanced,,skeletal muscle: 127.5,heart muscle: 46.5,Cell line enhanced,,REH: 15.0;RH-30: 17.3;SH-SY5Y: 23.2
26,CTD-2207O23.12,,ENSG00000267952,,19,7507052-7519622,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 5.6;skeletal muscle: 4.6,kidney: 2.9,Cell line enhanced,,AF22: 10.9;ASC diff: 8.4;fHDF/TERT166: 10.6;HBF TERT88: 6.7
27,DDIT4L,"REDD2, Rtp801L",ENSG00000145358,DNA damage inducible transcript 4 like,4,100185870-100190782,Predicted intracellular proteins,Evidence at protein level,HPA050903,,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Actin filaments,Endometrial cancer:5.77e-4 (favourable),Tissue enhanced,Tissue enhanced,,skeletal muscle: 113.3,"cervix, uterine: 33.2",Cell line enhanced,,ASC TERT1: 13.5;BJ: 25.0;fHDF/TERT166: 12.5;HSkMC: 10.7;RPTEC TERT1: 15.6
28,DENND2C,"dJ1156J9.1, DKFZp686G0351, DKFZp779P1149, FLJ37099, RP5-1156J9.1",ENSG00000175984,DENN domain containing 2C,1,114582848-114670422,Predicted intracellular proteins,Evidence at protein level,HPA054955,Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,esophagus: 19.5;skeletal muscle: 14.3;skin: 14.8,testis: 10.0,Cell line enhanced,,U-2197: 10.9;U-266/70: 19.3
29,DES,"CMD1I, CSM1, CSM2",ENSG00000175084,Desmin,2,219418377-219426739,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000034, HPA018803",Enhanced,,Supported,Intermediate filaments,Renal cancer:5.08e-4 (unfavourable),Expressed in all,Tissue enhanced,,heart muscle: 4151.2;skeletal muscle: 5462.0;smooth muscle: 3601.2,seminal vesicle: 3128.9,Cell line enhanced,,HSkMC: 50.9;LHCN-M2: 120.4;RH-30: 321.1
30,DUSP26,"DUSP24, MGC1136",ENSG00000133878,Dual specificity phosphatase 26,8,33591332-33600106,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018221,Approved,,Supported,Nucleus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 47.1;skeletal muscle: 138.7,ovary: 39.6,Group enriched,29.0,SCLC-21H: 110.0;SH-SY5Y: 23.6
31,DYRK1B,MIRK,ENSG00000105204,Dual specificity tyrosine phosphorylation regulated kinase 1B,19,39825350-39834201,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028522, HPA028786",Uncertain,,Approved,Nucleus,Renal cancer:8.83e-4 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 37.4,testis: 33.6,Cell line enhanced,,SCLC-21H: 15.0;SH-SY5Y: 15.3
32,FLNC,"ABP-280, ABPL, FLN2",ENSG00000128591,Filamin C,7,128830377-128859274,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA006135,Enhanced,,Supported,Plasma membrane<br>Cytosol,"Lung cancer:2.17e-5 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Glioma:2.14e-4 (unfavourable), Renal cancer:5.69e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 384.7,smooth muscle: 160.7,Cell line enhanced,,BJ: 331.0;hTEC/SVTERT24-B: 190.2;U-2 OS: 169.5
33,FNDC5,FRCP2,ENSG00000160097,Fibronectin type III domain containing 5,1,32862268-32872482,Predicted membrane proteins,Evidence at protein level,HPA051290,Approved,,,,,Group enriched,Tissue enhanced,,skeletal muscle: 110.2,heart muscle: 26.5,Cell line enhanced,,RH-30: 45.0;SCLC-21H: 9.3
34,GADL1,,ENSG00000144644,Glutamate decarboxylase like 1,3,30726200-30894765,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039160, HPA040229",Uncertain,,Approved,Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,skeletal muscle: 9.0,thyroid gland: 2.5,Cell line enhanced,,HAP1: 5.0
35,GATS,"DKFZp686B07267, STAG3OS",ENSG00000239521,"GATS, stromal antigen 3 opposite strand",7,100200653-100272218,Predicted intracellular proteins,Evidence at transcript level,HPA043176,Uncertain,,,,Cervical cancer:7.56e-7 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 3.3;skeletal muscle: 2.2,bone marrow: 0.7,Cell line enhanced,,A549: 1.4
36,GPD1,,ENSG00000167588,Glycerol-3-phosphate dehydrogenase 1,12,50103819-50111319,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA044620,Enhanced,,,,,Mixed,Tissue enhanced,,adipose tissue: 636.1;skeletal muscle: 195.7,kidney: 148.1,Cell line enhanced,,ASC diff: 86.3;CACO-2: 22.1;Hep G2: 17.0;RPMI-8226: 20.7
37,GRIP2,KIAA1719,ENSG00000144596,Glutamate receptor interacting protein 2,3,14489111-14556075,Predicted intracellular proteins,Evidence at transcript level,HPA035673,,,Approved,Cytosol,,Mixed,Tissue enhanced,,skeletal muscle: 12.4,heart muscle: 8.6,Cell line enhanced,,BJ hTERT+: 2.5;NTERA-2: 2.1;PC-3: 5.7;SCLC-21H: 4.0;U-2 OS: 2.4
38,HHATL,"C3orf3, GUP1, KIAA1173, MBOAT3, MSTP002, OACT3",ENSG00000010282,Hedgehog acyltransferase-like,3,42692663-42702827,Predicted membrane proteins,Evidence at protein level,HPA018174,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,heart muscle: 333.1;skeletal muscle: 97.6,cerebral cortex: 53.3,Not detected,,
39,HOXC9,"HOX3, HOX3B",ENSG00000180806,Homeobox C9,12,53994895-54003337,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA063965, HPA072160",,,Enhanced,Nucleoplasm,,Mixed,Tissue enhanced,,skeletal muscle: 6.2,adipose tissue: 3.3,Cell line enhanced,,AN3-CA: 19.7;HDLM-2: 26.0;HEK93: 30.3
40,HSPB6,"FLJ32389, Hsp20, PPP1R91",ENSG00000004776,Heat shock protein family B (small) member 6,19,35754569-35758079,Predicted intracellular proteins,Evidence at protein level,"CAB001974, HPA044153, HPA054811",Enhanced,,,,"Urothelial cancer:1.43e-6 (unfavourable), Renal cancer:1.93e-5 (unfavourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 843.0,adipose tissue: 666.5,Cell line enhanced,,ASC diff: 1220.3;ASC TERT1: 521.5;HHSteC: 505.3;HSkMC: 510.5
41,HSPB7,cvHSP,ENSG00000173641,Heat shock protein family B (small) member 7,1,16014028-16019594,Predicted intracellular proteins,Evidence at protein level,HPA027639,Approved,,Approved,Nucleoplasm,"Urothelial cancer:1.26e-4 (unfavourable), Head and neck cancer:5.29e-4 (unfavourable)",Mixed,Tissue enhanced,,heart muscle: 1571.0;skeletal muscle: 639.6,adipose tissue: 342.4,Cell line enriched,5.0,fHDF/TERT166: 246.0
42,IP6K3,"IHPK3, INSP6K3",ENSG00000161896,Inositol hexakisphosphate kinase 3,6,33721670-33746905,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053644,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:6.09e-4 (unfavourable),Mixed,Tissue enhanced,,skeletal muscle: 32.4;thyroid gland: 21.9,heart muscle: 9.1,Cell line enhanced,,HHSteC: 18.4;LHCN-M2: 30.1;RH-30: 15.3
43,JPH2,JP-2,ENSG00000149596,Junctophilin 2,20,44111695-44187578,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA052646,Approved,,,,,Mixed,Tissue enhanced,,skeletal muscle: 72.1;smooth muscle: 56.0,seminal vesicle: 47.8,Cell line enhanced,,EFO-21: 21.6;fHDF/TERT166: 18.5;SiHa: 16.8
44,KCNJ11,"BIR, Kir6.2",ENSG00000187486,Potassium voltage-gated channel subfamily J member 11,11,17385859-17389331,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA048891,Approved,,,,Renal cancer:1.56e-4 (favourable),Mixed,Tissue enhanced,,skeletal muscle: 32.7,cerebral cortex: 10.2,Cell line enhanced,,HEK93: 12.0;MCF7: 8.2;SCLC-21H: 10.3
45,KLHL30,FLJ43374,ENSG00000168427,Kelch like family member 30,2,238138722-238152947,Predicted intracellular proteins,Evidence at transcript level,HPA062095,,,Approved,Microtubule organizing center,,Mixed,Tissue enhanced,,skeletal muscle: 22.1,heart muscle: 5.6,Cell line enhanced,,BEWO: 3.1;RH-30: 4.4;THP-1: 1.5
46,KLHL31,"bA345L23.2, BKLHD6, KBTBD1",ENSG00000124743,Kelch like family member 31,6,53647901-53665708,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,heart muscle: 29.4;skeletal muscle: 51.2,adipose tissue: 9.0,Cell line enhanced,,SCLC-21H: 1.2
47,LINGO4,LRRN6D,ENSG00000213171,Leucine rich repeat and Ig domain containing 4,1,151800264-151806154,Predicted membrane proteins,Evidence at transcript level,HPA060781,Uncertain,,,,,Mixed,Tissue enhanced,,adrenal gland: 2.2;skeletal muscle: 4.1,"fallopian tube,prostate: 1.0",Not detected,,
48,LMO1,"RBTN1, RHOM1, TTG1",ENSG00000166407,LIM domain only 1,11,8224304-8268716,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,skeletal muscle: 10.1;skin: 5.9,epididymis: 2.0,Group enriched,6.0,HeLa: 22.0;SCLC-21H: 14.8;SH-SY5Y: 41.0;SiHa: 8.4
49,LRRC20,"FLJ10751, FLJ10844",ENSG00000172731,Leucine rich repeat containing 20,10,70298970-70382650,Predicted intracellular proteins,Evidence at protein level,HPA039630,,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:1.41e-4 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 120.5,heart muscle: 28.5,Cell line enhanced,,U-2 OS: 83.3
50,LRTM1,HT017,ENSG00000144771,Leucine rich repeats and transmembrane domains 1,3,54918237-54967088,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 9.3;spleen: 8.9,esophagus: 4.3,Cell line enhanced,,HEL: 1.0
51,LSMEM2,"C3orf45, FLJ38608",ENSG00000179564,Leucine rich single-pass membrane protein 2,3,50279027-50288114,Predicted membrane proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,heart muscle: 15.4;skeletal muscle: 5.4,testis: 2.8,Not detected,,
52,MAMSTR,"FLJ36070, MASTR",ENSG00000176909,MEF2 activating motif and SAP domain containing transcriptional regulator,19,48712742-48719721,Predicted intracellular proteins,Evidence at transcript level,HPA049765,,,Approved,Nuclear speckles,,Expressed in all,Tissue enhanced,,adrenal gland: 21.4;skeletal muscle: 31.4,fallopian tube: 10.4,Cell line enhanced,,RH-30: 16.1
53,MIB2,"FLJ39787, skeletrophin, ZZANK1, ZZZ5",ENSG00000197530,Mindbomb E3 ubiquitin protein ligase 2,1,1615415-1630610,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA068322,Enhanced,,,,,Expressed in all,Tissue enhanced,,skeletal muscle: 12.4,cerebral cortex: 4.4,Cell line enhanced,,SCLC-21H: 18.4
54,MLIP,"C6orf142, CIP, MGC18257",ENSG00000146147,Muscular LMNA interacting protein,6,53929982-54266280,Predicted intracellular proteins,Evidence at protein level,"HPA029252, HPA046654",Approved,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,heart muscle: 112.5;liver: 67.0;skeletal muscle: 45.7,skin: 20.6,Group enriched,7.0,HUVEC TERT2: 16.4;SK-MEL-30: 14.9
55,MN1,"MGCR, MGCR1, MGCR1-PEN",ENSG00000169184,"MN1 proto-oncogene, transcriptional regulator",22,27748277-27801498,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA003072,Approved,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,skeletal muscle: 22.0,cerebral cortex: 6.4,Cell line enhanced,,AF22: 31.4;RH-30: 12.4;TIME: 16.8;U-2 OS: 17.9;U-2197: 17.1
56,MRLN,"Linc-RAM, LINC00948, M1, MLN, MUSER1",ENSG00000227877,Myoregulin,10,59736692-59756041,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 65.4,kidney: 13.8,Cell line enriched,12.0,RH-30: 21.4
57,MSTN,GDF8,ENSG00000138379,Myostatin,2,190055697-190062729,"Disease related genes, Predicted secreted proteins",Evidence at protein level,CAB009963,Approved,,,,Glioma:3.98e-4 (favourable),Tissue enriched,Tissue enhanced,,skeletal muscle: 3.4,"cerebral cortex,endometrium: 1.3",Group enriched,13.0,LHCN-M2: 21.5;RH-30: 50.3
58,MYF5,bHLHc2,ENSG00000111049,Myogenic factor 5,12,80716912-80719673,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA041691,,,Supported,Nucleoplasm,,Not detected,Tissue enhanced,,skeletal muscle: 1.9,prostate: 0.4,Cell line enriched,19.0,LHCN-M2: 398.0
59,MYLK3,"caMLCK, MLCK",ENSG00000140795,Myosin light chain kinase 3,16,46703369-46790407,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA073447,Enhanced,,,,,Not detected,Tissue enhanced,,heart muscle: 69.4;skeletal muscle: 16.9,testis: 11.7,Cell line enhanced,,BEWO: 12.5;HEL: 36.3;K-562: 5.8;SK-BR-3: 6.2
60,MYLK4,SgK085,ENSG00000145949,Myosin light chain kinase family member 4,6,2663629-2750966,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA015860,Uncertain,,,,,Mixed,Tissue enhanced,,skeletal muscle: 9.8,kidney: 3.1,Cell line enriched,7.0,HEL: 6.4
61,NANOS1,"NOS1, ZC2HC12A",ENSG00000188613,Nanos C2HC-type zinc finger 1,10,119029716-119033732,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,CAB012219,Approved,,Supported,Nucleoplasm<br>Cytosol,Breast cancer:1.52e-4 (unfavourable),Mixed,Tissue enhanced,,skeletal muscle: 13.2,thyroid gland: 11.9,Cell line enhanced,,SH-SY5Y: 85.4;SK-BR-3: 34.9;SK-MEL-30: 28.2
62,NDUFS7,"CI-20, FLJ45860, FLJ46880, PSST",ENSG00000115286,NADH:ubiquinone oxidoreductase core subunit S7,19,1383527-1395589,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:4.90e-7 (favourable), Cervical cancer:2.03e-4 (favourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 96.7,duodenum: 40.7,Mixed,,
63,NEURL1,"h-neu, neu-1, NEURL, RNF67",ENSG00000107954,Neuralized E3 ubiquitin protein ligase 1,10,103493979-103592552,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA044204,Uncertain,,,,,Mixed,Tissue enhanced,,skeletal muscle: 50.9,cerebral cortex: 30.1,Cell line enhanced,,BEWO: 13.2;SCLC-21H: 20.2;SiHa: 9.4
64,NEXN,"NELIN, nexilin",ENSG00000162614,Nexilin F-actin binding protein,1,77888513-77943895,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA011185,Approved,,,,Colorectal cancer:5.60e-4 (unfavourable),Mixed,Tissue enhanced,,heart muscle: 298.6;skeletal muscle: 248.9,prostate: 109.6,Cell line enhanced,,BJ: 129.6;LHCN-M2: 116.4;RH-30: 106.0
65,NOS1,"nNOS, NOS",ENSG00000089250,Nitric oxide synthase 1,12,117208142-117452170,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002167, HPA058312",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enhanced,,skeletal muscle: 12.9,cerebral cortex: 3.0,Cell line enhanced,,HaCaT: 4.0;RH-30: 9.0;RPTEC TERT1: 4.4
66,NT5C1A,"CN-I, CN-IA, CN1, CN1A, MGC119199, MGC119201",ENSG00000116981,"5'-nucleotidase, cytosolic IA",1,39659121-39672038,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA050283, HPA054158",Supported,,,,,Not detected,Tissue enhanced,,heart muscle: 7.5;skeletal muscle: 24.9,cerebral cortex: 4.8,Cell line enriched,20.0,SH-SY5Y: 18.9
67,P2RX6,"MGC129625, P2RXL1, P2X6, P2XM",ENSG00000099957,Purinergic receptor P2X 6,22,21009808-21028830,Predicted membrane proteins,Evidence at protein level,"HPA028776, HPA028777",Approved,,Approved,Nucleoli<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 3.4;skeletal muscle: 3.0,spleen: 2.3,Cell line enhanced,,LHCN-M2: 5.6;RH-30: 4.0;U-87 MG: 11.5
68,PACSIN3,SDPIII,ENSG00000165912,Protein kinase C and casein kinase substrate in neurons 3,11,47177525-47186443,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039480, HPA043904",Approved,Approved,Supported,Plasma membrane<br>Cytosol,Ovarian cancer:2.09e-4 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 164.2,heart muscle: 93.6,Mixed,,
69,PADI2,"KIAA0994, PDI2",ENSG00000117115,Peptidyl arginine deiminase 2,1,17066761-17119435,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047735,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 85.0;colon: 89.8;rectum: 99.9;skeletal muscle: 108.6,breast: 48.8,Group enriched,5.0,A549: 10.4;RPTEC TERT1: 25.1;SK-BR-3: 38.1;T-47d: 13.1
70,PDLIM3,ALP,ENSG00000154553,PDZ and LIM domain 3,4,185500660-185535612,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA004749,Enhanced,,,,"Renal cancer:4.97e-7 (unfavourable), Thyroid cancer:2.13e-6 (unfavourable), Liver cancer:7.22e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 1097.6,seminal vesicle: 292.1,Cell line enhanced,,LHCN-M2: 125.9;RH-30: 35.3;U-266/70: 91.6
71,PEBP4,"CORK1, hPEBP4, MGC22776",ENSG00000134020,Phosphatidylethanolamine binding protein 4,8,22713251-23000000,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA025064,Uncertain,,,,,Group enriched,Tissue enhanced,,epididymis: 470.5;lung: 173.6;skeletal muscle: 233.0,thyroid gland: 96.3,Cell line enriched,7.0,U-266/70: 3.0
72,PHKA1,PHKA,ENSG00000067177,Phosphorylase kinase regulatory subunit alpha 1,X,72578814-72714319,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA001081,Enhanced,,Approved,Vesicles,Endometrial cancer:6.84e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 40.1;skeletal muscle: 35.5,adrenal gland: 15.6,Mixed,,
73,PKIA,PRKACN1,ENSG00000171033,CAMP-dependent protein kinase inhibitor alpha,8,78516139-78605267,Predicted intracellular proteins,Evidence at protein level,HPA042791,Uncertain,,,,Stomach cancer:5.41e-4 (unfavourable),Mixed,Tissue enhanced,,skeletal muscle: 407.4,"heart muscle,parathyroid gland: 123.6",Cell line enhanced,,HUVEC TERT2: 86.5;RT4: 79.9
74,PLCD4,,ENSG00000115556,Phospholipase C delta 4,2,218607765-218637184,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009914, HPA038139, HPA038140",Enhanced,,Approved,Nuclear membrane<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,skeletal muscle: 38.4,testis: 9.7,Cell line enhanced,,SH-SY5Y: 21.8
75,PPP1R1A,,ENSG00000135447,Protein phosphatase 1 regulatory inhibitor subunit 1A,12,54575387-54588659,Predicted intracellular proteins,Evidence at protein level,"CAB007811, HPA041542",Approved,,,,Endometrial cancer:2.36e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,adipose tissue: 252.9;skeletal muscle: 291.2,kidney: 74.4,Cell line enhanced,,ASC diff: 6.1;NTERA-2: 29.5;RPTEC TERT1: 24.5
76,PPP1R3C,"PPP1R5, PTG",ENSG00000119938,Protein phosphatase 1 regulatory subunit 3C,10,91628442-91633054,Predicted intracellular proteins,Evidence at protein level,HPA027041,Uncertain,,,,,Expressed in all,Tissue enhanced,,skeletal muscle: 322.7,heart muscle: 111.2,Cell line enhanced,,HHSteC: 43.7;LHCN-M2: 86.1
77,PPP2R3A,PPP2R3,ENSG00000073711,Protein phosphatase 2 regulatory subunit B''alpha,3,135965673-136147891,Predicted intracellular proteins,Evidence at protein level,"HPA035829, HPA035830, HPA065338",Uncertain,,Approved,Golgi apparatus,"Pancreatic cancer:1.14e-5 (unfavourable), Renal cancer:1.15e-5 (favourable), Urothelial cancer:3.91e-4 (unfavourable), Endometrial cancer:4.38e-4 (unfavourable)",Mixed,Tissue enhanced,,skeletal muscle: 63.3,heart muscle: 34.3,Mixed,,
78,PPP2R3B,"PPP2R3L, PPP2R3LY, PR48",ENSG00000167393,Protein phosphatase 2 regulatory subunit B''beta,X,333963-386955,Predicted intracellular proteins,Evidence at protein level,HPA074545,,,Uncertain,Endoplasmic reticulum,"Urothelial cancer:1.90e-5 (favourable), Pancreatic cancer:2.92e-5 (favourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 14.7,heart muscle: 4.6,Cell line enhanced,,PC-3: 20.0;U-698: 23.8
79,PRKCQ,,ENSG00000065675,Protein kinase C theta,10,6427143-6580301,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA065279, HPA073098",,,Enhanced,Microtubule organizing center,Thyroid cancer:5.27e-4 (unfavourable),Mixed,Tissue enhanced,,skeletal muscle: 43.0,thyroid gland: 25.0,Cell line enhanced,,HEL: 50.9;MOLT-4: 34.7
80,PROB1,C5orf65,ENSG00000228672,Proline rich basic protein 1,5,139390592-139395713,Predicted intracellular proteins,Evidence at protein level,HPA060103,Enhanced,,Approved,Nucleoplasm,Cervical cancer:9.26e-4 (favourable),Mixed,Tissue enhanced,,skeletal muscle: 24.8,heart muscle: 6.0,Cell line enriched,6.0,HDLM-2: 97.1
81,PRSS56,,ENSG00000237412,"Protease, serine 56",2,232520463-232525716,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 3.4,testis: 0.8,Not detected,,
82,PTGES3L,,ENSG00000267060,Prostaglandin E synthase 3 like,17,42968088-42980433,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,heart muscle: 30.2;skeletal muscle: 58.7,smooth muscle: 16.3,Cell line enhanced,,THP-1: 17.1
83,RASA4B,,ENSG00000170667,RAS p21 protein activator 4B,7,102482445-102517781,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at transcript level,HPA043010,Uncertain,,Uncertain,Vesicles<br>Cell Junctions,,Not detected,Tissue enhanced,,skeletal muscle: 39.7,cerebral cortex: 15.7,Cell line enhanced,,SH-SY5Y: 14.3;U-138 MG: 18.0;U-2 OS: 16.6
84,RBM24,"dJ259A10.1, FLJ30829, RNPC6",ENSG00000112183,RNA binding motif protein 24,6,17281346-17293875,Predicted intracellular proteins,Evidence at protein level,"HPA066927, HPA067231",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,heart muscle: 90.9;skeletal muscle: 109.8,endometrium: 51.6,Cell line enhanced,,LHCN-M2: 49.0;RH-30: 57.9;T-47d: 26.5
85,RP11-211G3.2,,ENSG00000223401,,3,187743686-187746028,Predicted intracellular proteins,Evidence at transcript level,,,,,,Breast cancer:6.93e-4 (favourable),Mixed,Tissue enhanced,,skeletal muscle: 8.0,bone marrow: 4.5,Cell line enhanced,,Daudi: 2.1;U-698: 4.6
86,RP11-618P17.4,,ENSG00000266953,,19,34396315-34409364,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,skeletal muscle: 3.0,stomach: 0.7,Mixed,,
87,RRAD,"RAD, REM3",ENSG00000166592,"RRAD, Ras related glycolysis inhibitor and calcium channel regulator",16,66921679-66925644,Predicted intracellular proteins,Evidence at protein level,HPA041755,Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,,Expressed in all,Tissue enhanced,,heart muscle: 98.8;skeletal muscle: 67.5,esophagus: 62.8,Group enriched,8.0,HDLM-2: 166.9;U-87 MG: 48.4
88,RXRG,NR2B3,ENSG00000143171,Retinoid X receptor gamma,1,165400917-165445355,"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB002615, HPA012933",Uncertain,,Supported,Nucleoplasm<br>Nuclear bodies,Thyroid cancer:9.40e-5 (favourable),Group enriched,Tissue enhanced,,skeletal muscle: 16.7,"cervix, uterine: 4.7",Cell line enriched,6.0,SK-MEL-30: 29.1
89,SBK1,Sbk,ENSG00000188322,SH3 domain binding kinase 1,16,28292519-28323849,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,Cervical cancer:6.88e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 10.9;skeletal muscle: 12.0,parathyroid gland: 4.1,Cell line enhanced,,AF22: 27.9;NTERA-2: 29.2;REH: 29.2;SCLC-21H: 52.5;SH-SY5Y: 44.5
90,SCN1B,,ENSG00000105711,Sodium voltage-gated channel beta subunit 1,19,35030466-35040449,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Pancreatic cancer:1.38e-4 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 145.1,cerebral cortex: 52.4,Cell line enhanced,,A549: 15.7;TIME: 21.3
91,SCX,"bHLHa41, bHLHa48, SCXA, SCXB",ENSG00000260428,Scleraxis bHLH transcription factor,8,144266560-144268481,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA043183,Uncertain,,,,Glioma:2.46e-4 (unfavourable),Group enriched,Tissue enhanced,,skeletal muscle: 5.3,parathyroid gland: 2.9,Cell line enhanced,,BEWO: 4.9;HaCaT: 5.0
92,SEMA6C,KIAA1869,ENSG00000143434,Semaphorin 6C,1,151131685-151146664,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,"HPA076150, HPA077625",,,Approved,Nucleoplasm<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 111.3,testis: 33.8,Cell line enhanced,,AF22: 13.8;HUVEC TERT2: 20.6
93,SGCA,"A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1",ENSG00000108823,Sarcoglycan alpha,17,50164214-50175931,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA007537,Uncertain,,,,,Mixed,Tissue enhanced,,heart muscle: 79.5;skeletal muscle: 181.4,seminal vesicle: 38.3,Cell line enriched,13.0,LHCN-M2: 65.0
94,SGCG,"A4, DAGA4, DMDA, DMDA1, LGMD2C, MAM, MGC130048, SCARMD2, SCG3, TYPE",ENSG00000102683,Sarcoglycan gamma,13,23180952-23325165,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA007476, HPA011922",Enhanced,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,heart muscle: 74.9;skeletal muscle: 54.0,adipose tissue: 14.5,Cell line enriched,5.0,fHDF/TERT166: 50.4
95,SHISA4,"C1orf40, hShisa4, TMEM58",ENSG00000198892,Shisa family member 4,1,201888680-201892306,Predicted membrane proteins,Evidence at protein level,HPA061273,Uncertain,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 45.3;skeletal muscle: 94.4,adrenal gland: 23.6,Mixed,,
96,SLC25A4,"ANT1, PEO2, PEO3, T1",ENSG00000151729,Solute carrier family 25 member 4,4,185143241-185150382,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA046835, HPA071684",Approved,,Enhanced,Mitochondria,"Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable)",Expressed in all,Tissue enhanced,,heart muscle: 122.1;skeletal muscle: 66.2,cerebral cortex: 38.1,Mixed,,
97,SLC29A2,"DER12, ENT2, HNP36",ENSG00000174669,Solute carrier family 29 member 2,11,66362521-66372214,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA018168,Approved,,Uncertain,Nucleoplasm,"Endometrial cancer:2.04e-4 (unfavourable), Renal cancer:2.78e-4 (favourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 36.4,parathyroid gland: 21.9,Cell line enhanced,,CAPAN-2: 37.2;T-47d: 48.0
98,SLC2A4,GLUT4,ENSG00000181856,Solute carrier family 2 member 4,17,7281667-7288257,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB016544,Enhanced,,,,,Mixed,Tissue enhanced,,heart muscle: 32.6;skeletal muscle: 45.0,adipose tissue: 21.8,Cell line enhanced,,Hep G2: 3.7
99,SNAI3,"SMUC, Zfp293, ZNF293",ENSG00000185669,Snail family transcriptional repressor 3,16,88677682-88686493,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA071127,,,Approved,Nucleoplasm,"Cervical cancer:1.39e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable)",Mixed,Tissue enhanced,,skeletal muscle: 10.9,lymph node: 4.3,Cell line enhanced,,NB-4: 11.5;RPMI-8226: 19.9
100,SPTB,,ENSG00000070182,"Spectrin beta, erythrocytic",14,64746283-64879883,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003394, HPA003398, CAB015169, CAB016232",Enhanced,,Uncertain,Golgi apparatus<br>Cytosol,,Mixed,Tissue enhanced,,bone marrow: 38.3;skeletal muscle: 43.1,heart muscle: 15.1,Cell line enhanced,,HEL: 35.6;K-562: 43.0;U-937: 11.1
101,SRPK3,"MSSK1, STK23",ENSG00000184343,SRSF protein kinase 3,X,153776412-153785732,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,heart muscle: 28.7;skeletal muscle: 73.6,prostate: 10.9,Cell line enhanced,,RH-30: 45.4
102,STBD1,"FLJ41801, GENX-3414",ENSG00000118804,Starch binding domain 1,4,76306026-76311599,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA011952, HPA012849",Enhanced,,Supported,Cytosol,,Mixed,Tissue enhanced,,adipose tissue: 46.7;skeletal muscle: 32.8,liver: 14.5,Cell line enhanced,,HDLM-2: 24.3;Karpas-707: 37.9;U-266/70: 25.8
103,SYNPO,KIAA1029,ENSG00000171992,Synaptopodin,5,150601080-150659220,Predicted intracellular proteins,Evidence at protein level,"CAB033265, HPA034631, CAB037325, HPA071347",Enhanced,,Approved,Nucleoplasm<br>Actin filaments<br>Cytosol,Renal cancer:1.53e-6 (unfavourable),Expressed in all,Tissue enhanced,,skeletal muscle: 446.6,heart muscle: 226.3,Cell line enhanced,,BEWO: 85.1;TIME: 144.5;U-87 MG: 148.8
104,TBX1,"CATCH22, VCF",ENSG00000184058,T-box 1,22,19756703-19783593,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029330,,,Approved,Nuclear bodies<br>Cytoplasmic bodies,Urothelial cancer:8.90e-4 (favourable),Mixed,Tissue enhanced,,skeletal muscle: 23.0,testis: 10.5,Cell line enhanced,,K-562: 107.3;TIME: 35.1
105,TCEA3,TFIIS.H,ENSG00000204219,Transcription elongation factor A3,1,23381061-23424740,Predicted intracellular proteins,Evidence at protein level,"HPA044960, HPA055811",Approved,,Approved,Nucleoplasm<br>Vesicles,Head and neck cancer:2.56e-4 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 157.4,ovary: 62.8,Cell line enhanced,,Hep G2: 43.0;SiHa: 21.8;T-47d: 30.3
106,TEAD4,"EFTR-2, RTEF-1, TCF13L1, TEF-3, TEFR-1",ENSG00000197905,TEA domain transcription factor 4,12,2959330-3040673,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA056896,Uncertain,,Supported,Nucleoplasm,Renal cancer:9.78e-9 (unfavourable),Tissue enriched,Tissue enhanced,,skeletal muscle: 38.8,thyroid gland: 17.8,Cell line enhanced,,HBEC3-KT: 263.0
107,TMEM110-MUSTN1,,ENSG00000248592,TMEM110-MUSTN1 readthrough,3,52833121-52897562,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA051855,Uncertain,,Approved,Cytosol,,Not detected,Tissue enhanced,,skeletal muscle: 11.1,adipose tissue: 6.6,Cell line enhanced,,HDLM-2: 5.2
108,TMEM143,FLJ10922,ENSG00000161558,Transmembrane protein 143,19,48332356-48364237,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014476,Uncertain,,Approved,Nucleoli fibrillar center,Renal cancer:1.53e-7 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 32.5,heart muscle: 15.5,Expressed in all,,
109,TMEM266,"C15orf27, FLJ38190",ENSG00000169758,Transmembrane protein 266,15,76059837-76229121,Predicted membrane proteins,Evidence at protein level,"HPA041921, HPA049425",Enhanced,,Supported,Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 1.9;skeletal muscle: 1.5,placenta: 1.2,Cell line enhanced,,NTERA-2: 1.0
110,TMEM52,,ENSG00000178821,Transmembrane protein 52,1,1917590-1919273,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,pancreas: 38.8;skeletal muscle: 105.7,adrenal gland: 24.4,Cell line enhanced,,Hep G2: 13.9;RPMI-8226: 25.7
111,TNFRSF13B,"CD267, IGAD2, TACI",ENSG00000240505,TNF receptor superfamily member 13B,17,16929816-16972118,"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030453,Uncertain,,,,,Not detected,Tissue enhanced,,lymph node: 20.3;skeletal muscle: 22.1;spleen: 27.2;tonsil: 21.0,appendix: 12.1,Group enriched,8.0,Karpas-707: 120.9;RPMI-8226: 76.1;U-266/70: 56.5
112,TRIM54,"MURF, MURF-3, RNF30",ENSG00000138100,Tripartite motif containing 54,2,27282392-27307439,Predicted intracellular proteins,Evidence at protein level,HPA019690,Uncertain,,,,Renal cancer:6.46e-4 (unfavourable),Mixed,Tissue enhanced,,heart muscle: 63.9;skeletal muscle: 181.1,epididymis: 30.7,Group enriched,13.0,HAP1: 7.4;NTERA-2: 15.3
